

02- 13- 06.

DW

Attorney Docket No. 1834.01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Cimbora et al. )

Application No.: 10/690,276 )

Filed: October 20, 2003 )

For: COMPOSITIONS AND METHODS )  
FOR TREATING )  
INFLAMMATORY DISORDERS )

Group Art Unit: 1647

Examiner: J. Lockard

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 329263443 US

Date of Deposit: February 9, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stacey L. Stamper  
Stacey L. Stamper

2/9/06  
Date

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above application. Issuance of a corrected filing receipt in accordance with the annotations on the attached Filing Receipt copy is respectfully requested.

The errors to be corrected are as follows:


**In the Domestic Priority data as claimed by applicant**

After "and claims benefit of 60/307,233 07/23/2001" please add  
--and claims benefit of 60/343,818 10/25/01--.

Appl. No. 10/690,276  
Req. for Corrected FR dated Feb. 9, 2006

These corrections are not due to any errors by applicant and no fee is due.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Herbert L. Ley III', with a long horizontal flourish extending to the right.

Herbert L. Ley III, Ph.D.  
Registration No. 53,215

Intellectual Property Department  
**Myriad Genetics, Inc.**  
**(Customer No. 26698)**  
320 Wakara Way  
Salt Lake City, UT 84108  
Telephone: 801-584-3600  
Fax: 801-883-3871

Date: February 9, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/690,276	10/20/2003	1647	770	1834.01	34	20	2

CONFIRMATION NO. 8598

26698  
 MYRIAD GENETICS INC.  
 LEGAL DEPARTMENT  
 320 WAKARA WAY  
 SALT LAKE CITY, UT 84108

MYRIAD GENETICS INC.  
 RECEIVED

APR 05 2004

UPDATED FILING RECEIPT



\*OC000000012242432\*

LAW DEPARTMENT

Date Mailed: 04/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Daniel Cimborra, Salt Lake City, UT;  
 Karen Heichman, Salt Lake City, UT;  
 Paul Bartel, Salt Lake City, UT;  
 Kimberly Mauck, Sandy, UT;  
 Angie Bush, Sandy, UT;

**Assignment For Published Patent Application**

Myriad Genetics, Incorporated, Salt Lake City, UT;

**Domestic Priority data as claimed by applicant**

This application is a CIP of 09/727,384 12/01/2000  
 which claims benefit of 60/168,377 12/02/1999  
 and claims benefit of 60/168,379 12/02/1999  
 and claims benefit of 60/185,056 02/25/2000 \*

This application 10/690,276  
 is a CIP of 10/035,344 01/04/2002  
 which claims benefit of 60/259,571 01/04/2001  
 and is a CIP of 10/035,343 01/04/2002  
 which claims benefit of 60/259,572 01/04/2001  
 This application 10/690,276

is a CIP of 10/099,924 03/14/2002  
 which claims benefit of 60/276,179 03/15/2001  
 and claims benefit of 60/307,233 07/23/2001

\* This application 10/690,276 and claims benefit of 60/343,818 10/25/01  
 is a CIP of 10/100,503 03/18/2002

which claims benefit of 60/277,013 03/19/2001  
This application 10/690,276  
is a CIP of 10/014,814 12/14/2001  
which claims benefit of 60/255,063 12/14/2000  
This application 10/690,276  
is a CIP of 10/024,599 12/21/2001  
which claims benefit of 60/256,986 12/21/2000  
(\*Data provided by applicant is not consistent with PTO records.

#### Foreign Applications

**Projected Publication Date:** To Be Determined - pending completion of Security Review

**Non-Publication Request:** No

**Early Publication Request:** No

#### Title

Compositions and methods for treating inflammatory disorders

#### Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).